Skip to Content

Marina Y. Konopleva, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor (tenure clinical appointment), Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor (clinical appointment), Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1998 Federal Institute of Hematology and Blood Transfusion, St.-Petersburg, Russian Federation, PHD, Experimental Hematology
1990 1st Pavlov Medical Institute, St.-Petersburg, MD, Medicine

Board Certifications

10/2013 American Board of Internal Medicine


Academic Appointments

Assistant Professor (tenure track clinical appointment), Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2008-8/2009
Assistant Professor (non-tenure track clinical appointment), Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2007-9/2008

Honors and Awards

2011-2016 Scholar in Clinical Research Award, Leukemia and Lymphoma Society
2011-2014 Faculty Scholar Award, UT MD Anderson Cancer Center
2010-2015 $750,000 Start-up Award, UT MD Anderson Cancer Center

Selected Publications

Peer-Reviewed Original Research Articles

1. Tabe Y, Jin L, Iwabuchi K, Wang RY, Ichikawa N, Miida T, Cortes J, Andreeff M, Konopleva M. Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts. Leukemia 26(5):883-92, 5/2012. e-Pub 10/2011. PMID: 22005789.
2. Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia 26(4):778-87, 4/2012. e-Pub 11/2011. PMCID: PMC3604791.
3. Konoplev S, Jorgensen JL, Thomas DA, Lin E, Burger J, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M. Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer. e-Pub 3/2011. PMID: 21456010.
4. Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, Borthakur G, Bueso-Ramos C, Shpall E, Thomas DA, Jordan CT, Kantarjian H, Wilson WR, Lock R, Andreeff M, Konopleva M. Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104. PLoS One 6(8):e23108, 2011. e-Pub 8/2011. PMCID: PMC3154919.
5. Konopleva M, Tabe Y, Zeng Z, Andreeff M.. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat 12(4-5):103-113, Aug-Oct, 8/2009. e-Pub 7/2009. PMCID: PMC3640296.
6. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, Andreeff M, Konopleva M.. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113(24):6215-24, 6/11/2009. e-Pub 10/27/2008. PMCID: PMC2699240.
7. Samudio I, Konopleva M, Carter B, Andreeff M. Apoptosis in leukemias: regulation and therapeutic targeting. Cancer Treat Res 145:197-217, 2009. PMID: 20306253.
8. Xu Y, Tabe Y, Jin L, Watt J, McQueen T, Ohsaka A, Andreeff M, Konopleva M. TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells. Br J Haematol 142(2):192-201, 6/2008. e-Pub 5/19/2008. PMID: 18492113.
9. Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 68(9):3413-20, 5/2008. PMCID: PMC4096127.
10. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M. Mutant FLT3: A direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 100(3):184-98, 2/6/2008. e-Pub 1/29/2008. PMID: 18230792.
11. Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H, Kimura S, Ohsaka A, Rios MB, Calvert L, Kantarjian H, Andreeff M, Konopleva M. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 7(1):48-58, 1/2008. PMID: 18202009.
12. Tabe Y, Jin L, Contractor R, Gold D, Ruvolo P, Radke S, Xu Y, Tsutusmi-Ishii Y, Miyake K, Miyake N, Kondo S, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. Cell Death Differ 14(8)(8):1443-1456, 8/2007. e-Pub 4/2007. PMID: 17464329.
13. Mullican SE, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Milbrandt J, Conneely OM. Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med 13(6):730-5, 6/2007. e-Pub 5/21/2007. PMID: 17515897.
14. Zeng Z, Sarbassov DD, Samudio IJ, Yee KW, Munsell MF, Jackson CE, Giles FJ, Sabatini DM, Andreeff M, Konopleva M. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109(8):3509-12, 4/2007. e-Pub 12/2006. PMCID: PMC1852241.
15. Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, Mills GB, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. Activation of integrin-linked kinase is a critical pro-survival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 67(2):684-94, 1/2007. PMID: 17234779.
16. Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, Estey E, Andreeff M, Konopleva M. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 5(12):3113-21, 12/2006. PMID: 17172414.
17. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff M. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10(5):375-88, 11/2006. PMID: 17097560.
18. Zeng Z, Samudio IJ, Zhang W, Estrov Z, Pelicano H, Harris D, Frolova O, Hail N, Jr, Chen W, Kornblau SM, Huang P, Lu Y, Mills GB, Andreeff M, Konopleva M. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 66(7):3737-46, 4/2006. PMID: 16585200.
19. Konopleva M, Zhang W, Shi YX, McQueen T, Tsao T, Abdelrahim M, Munsell MF, Johansen M, Yu D, Madden T, Safe SH, Hung MC, Andreeff M. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Mol Cancer Ther 5(2):317-28, 2/2006. PMID: 16505105.
20. Konopleva M, Shi Y, Steelman LS, Shelton JG, Munsell M, Marini F, McQueen T, Contractor R, McCubrey JA, Andreeff M. Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells. Cancer Res 65(21):9962-70, 11/1/2005. PMID: 16267021.
21. Konopleva M, Tsao T, Estrov Z, Lee RM, Wang RY, Jackson CE, McQueen T, Monaco G, Munsell M, Belmont J, Kantarjian H, Sporn MB, Andreeff M. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res 64(21):7927-35, 11/1/2004. PMID: 15520199.
22. Konopleva M, Elstner E, McQueen TJ, Tsao T, Sudarikov A, Hu W, Schober WD, Wang RY, Chism D, Kornblau SM, Younes A, Collins SJ, Koeffler HP, Andreeff M. Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 3(10):1249-62, 10/2004. PMID: 15486192.
23. Konopleva M, Cheng SC, Cortes JE, Hayes KJ, Pierce SA, Andreeff M, Giles FJ, O'Brien S, Kantarjian HM, Estey EH. Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts. Haematologica 88:733-6, 7/2003. PMID: 12857550.
24. Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 16:1713-24, 9/2002. PMID: 12200686.
25. Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, Zhao S, Harris D, Chang S, Jackson CE, Munsell M, Suh N, Gribble G, Honda T, May WS, Sporn MB, Andreeff M. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 99:326-35, 2002. PMID: 11756188.

Invited Articles

1. Konopleva MY, Jordan CT. Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting. J Clin Oncol 29(5):591-9, 2/2011. e-Pub 1/2011. PMID: 21220598.

Grant & Contract Support

Title: Hypoxia-selective Kinase Inhibitors for Leukemia Therapy
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/3/2013 - 3/31/2016
Title: DRP: "Real-time Metabolic Imaging of Leukemia By Hyperpolarization"
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Pratip Bhattacharya, PhD
Duration: 5/1/2012 - 4/30/2013
Title: Scholar in Clinical Research: "Biology and targeting of hypoxic microenvironment in leukemias"
Funding Source: Leukemia and Lymphoma Society
Role: Principal Investigator
Duration: 7/1/2011 - 6/30/2016
Title: Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2/1/2011 - 12/31/2015
Title: Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemias
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Duration: 4/5/2010 - 3/31/2014

Last updated: 8/10/2015